GlassScriptPhysician profile
Mary K Figaro
NPI 1710908181
$73,013.88
in general payments reported to CMS, 2019-2025
15 companies · $829 in 2025
The $829 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37K · 2020: $25K · 2021: $9,799 · 2022: $397 · 2023: $294 · 2024: $118 · 2025: $829.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $800 · Food and Beverage: $440.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $800.00 |
| Food and Beverage | $440.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $35,811.54 | 2019-2024 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14,031.60 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $11,804.12 | 2019-2021 | |
| Lilly USA, LLC | $10,322.27 | 2019-2025 | Jardiance, Mounjaro |
| Abbott Laboratories | $736.61 | 2019-2023 | Freestyle Libre 3 |
| Astellas Pharma US INC | $103.08 | 2024 | Veozah |
| Dexcom, INC. | $34.44 | 2021-2023 | Dexcom G6 Transmitter |
| Valeritas, INC. | $33.07 | 2019 | |
| Sanofi-Aventis U.S. LLC | $26.74 | 2020-2021 | |
| Shire North American Group INC | $23.29 | 2019 | |
| Tandem Diabetes Care, INC. | $22.00 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Xeris Pharmaceuticals, INC. | $20.25 | 2021 | |
| Insulet Corporation | $18.87 | 2023 | Omnipod |
| Corcept Therapeutics | $13.97 | 2019 | |
| Amgen INC. | $12.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Figaro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.